Connection
Preston Bratcher to Mutation
This is a "connection" page, showing publications Preston Bratcher has written about Mutation.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.356 |
|
|
|
-
Shaughnessy CA, Zeitlin PL, Bratcher PE. Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro. J Cyst Fibros. 2022 07; 21(4):637-643.
Score: 0.095
-
Bratcher PE, Zeitlin PL. Expanding CFTR Modulator Testing to Carriers of CFTR Variants. Ann Am Thorac Soc. 2021 11; 18(11):1776-1779.
Score: 0.093
-
Bratcher PE, Hunt KC, Pickard K, Taylor-Cousar JL. Positive clinical response to ivacaftor treatment in an individual with the CFTR genotype F508del/V456A. J Cyst Fibros. 2019 03; 18(2):e9-e10.
Score: 0.075
-
Bratcher PE, Rowe SM, Reeves G, Roberts T, Szul T, Harris WT, Tirouvanziam R, Gaggar A. Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor. J Cyst Fibros. 2016 Jan; 15(1):67-73.
Score: 0.059
-
Shaughnessy CA, Yadav S, Bratcher PE, Zeitlin PL. Receptor-mediated activation of CFTR via prostaglandin signaling pathways in the airway. Am J Physiol Lung Cell Mol Physiol. 2022 03 01; 322(3):L305-L314.
Score: 0.024
-
Rotman E, Bratcher P, Kuzminov A. Reduced lipopolysaccharide phosphorylation in Escherichia coli lowers the elevated ori/ter ratio in seqA mutants. Mol Microbiol. 2009 Jun; 72(5):1273-92.
Score: 0.010